Last reviewed · How we verify
NCT05162001
Body Weight Response With Disulfiram in Humans
EARLY_PHASE1 trial testing Disulfiram 250 mg in Obesity; Drug in 10 participants. Status unknown.
31 January 2022
Quick facts
| Lead sponsor | Universidad de Guanajuato |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 21 November 2021 |
| Primary completion | 31 January 2022 |
| Estimated completion | 30 April 2022 |
| Sites | 1 location across Mexico |
Drugs / interventions tested
- Disulfiram 250 mg — full drug profile →
Conditions studied
- Obesity; Drug — all drugs for Obesity; Drug →
Sponsor
Universidad de Guanajuato — full company profile →
Who can join
Adults 18 to 65, any sex, with Obesity; Drug. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Overweight and obesity due to food that exceeds the requirements is an increasingly common global problem. Lifestyle intervention and anorectic drugs result in minimal weight loss, which tends to be easily regained. In addition, drugs tend to have too many side effects and have had to be withdrawn from management schemes and even from the market. Disulfiram (Antabuse®️) is approved by the Food and Drug Administration against chronic alcohol addiction. In a mouse study, disulfiram prevented body weight gain and negated the adverse impact of an obesogenic diet on insulin; used properly it is a safe drug. Carrying out a testing-concept study with disulfiram will allow the establishment of guidelines on clinical studies focused on its use as an adjunct in the reduction and control of body weight.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Off-label and repurposed use of disulfiram beyond alcohol dependence: A systematic review of clinical and preclinical evidence.
Benkő BM, De Brito Parreirinha NS, Sebe I, Zelkó R. · · 2026 · PMID 42058920 · DOI 10.1016/j.isci.2026.115441
Verify or expand the search:
- PubMed search for NCT05162001
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Disulfiram 250 mg
Trials testing the same drug.
- NCT06793488 — Anxiety During Abstinence in AUD · EARLY_PHASE1 · recruiting
- NCT05626920 — Disulfiram for Treatment of Retinal Degeneration · Phase 1, PHASE2 · recruiting
Other recruiting trials for Obesity; Drug
Currently open trials in the same condition.
- NCT06431308 — Nutritional Therapy to Incretin-based Anti-obesity Medications in the Management of Gastrointestinal Adverse Events · NA · recruiting
- NCT05176626 — Long-term Effectiveness of the Antiobesity Medication Phentermine · Phase 4 · active not recruiting
Other Universidad de Guanajuato trials
Trials by the same sponsor.
- NCT06788054 — Intradialysis Exercise Functional Capacity, Body Composition and Survival in Hemodialysis Patients · NA · enrolling by invitation
- NCT06667180 — Effects of Low-intensity Transcranial Magnetic Stimulation on Major Depressive Disorder, and on 5-hydroxyindoleacetic Ac · Phase 1, PHASE2 · recruiting
- NCT05778266 — Effect of L-citrulline and HIIT on Arterial Stiffness, Body Composition, and Lipid Profile in Adolescents with Steatosis · NA · completed
- NCT04871360 — Effect of L-Citrulline Supplementation on NAFLD in Adolescents With Obesity · NA · completed
- NCT04636450 — Manual and Rotatory Instrumentation Pulpectomy in Primary Mandibular Molars · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05162001 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universidad de Guanajuato
- Last refreshed: 17 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05162001.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing